Abstract
Many research studies on various biomarkers were done, in analysing the prognosis and in evaluation of therapeutic target strategies which improves the survival rate in carcinoma of cervix. Of these, one of the important biomarker is HER-2/neu. To correlate histomorphology of cervical lesions, various clinicopathological parameters with HER-2/neu. The present study conducted during the period from June 2017 to May 2019 in department of Pathology, Madurai Medical College, Madurai. 200 cases were selected for study. Among those, 50 cases were selected for immunohistochemical studies with HER 2. Out of 50 cases included, higher HER 2 positivity was observed in HSIL as compared to LSIL. In malignant lesions, positive immunostaining was observed in 71.05% cases. Positivity was seen in 70% of cases of squamous cell carcinoma and 75% of cases of adenocarcinoma cases. Progression of clinical spectrum of the lesion is associated with overexpression if HER 2, suggesting HER 2 can be considered as one of poor prognostic factor. Malignant lesions expressed greater positivity than premalignant lesions. Also, overexpression of HER 2 is associated with progressing grade and advanced stage of cervical carcinoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
